PAS-003

PAS-003 is a **fully humanized monoclonal antibody** developed as a **potent inhibitor of the integrin alpha-5/beta-1 (α5β1) protein**, which is overexpressed in amyotrophic lateral sclerosis (ALS) patient and animal model tissues[1][3][5][7]. By binding and inhibiting this "velcro-like" integrin, PAS-003 is intended to reduce neuroinflammation, improve motor function, and increase survival, as demonstrated in preclinical models[1][5][7]. The drug is under development by Pasithea Therapeutics, working in collaboration with academic centers such as Stanford, Mayo Clinic, and Oregon Health & Science University[1][5][7]. The lead indication is ALS (both sporadic and familial forms), with the potential for other neurological disorders[3][5]. PAS-003 is a new molecular entity and is currently in the preclinical development stage[3][5].

Other names

Alpha-5 Pasithea TherapeuticsAlpha5 Pasithea TherapeuticsAlpha 5 Pasithea Therapeutics